FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000603887> ?p ?o ?g. }

• W2000603887 endingPage "31" @default.
• W2000603887 startingPage "30" @default.
• W2000603887 abstract "ContextGlycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors improve myocardial reperfusionand clinical outcomes of patients undergoing primary percutaneous coronaryintervention (PCI), but optimal timing of administration remains unclear.No systematic reviews have comprehensively examined the effects of early vsdelayed administration of these agents.ObjectiveTo perform a meta-analysis of randomized trials of early (prior to transferto the catheterization laboratory) vs late (at the time of PCI) intravenousadministration of Gp IIb/IIIa inhibitors in acute ST-segment elevation myocardialinfarction (STEMI).Data SourcesMEDLINE and the Cochrane Controlled Trials Register search of the literatureover the past 10 years; papers presented at major cardiac conferences; consultationwith national and international colleagues as well as Gp IIb/IIIa inhibitordrug manufacturers; and text and journal article bibliographies.Study Selection and Data ExtractionWe examined trials of randomized comparisons between early administrationat the point of initial contact (emergency department or ambulance) and lateadministration (catheterization laboratory) of Gp IIb/IIIa inhibitors in STEMI.Outcome data had to be available on both culprit artery patency evaluatedby Thrombolysis in Myocardial Infarction (TIMI) flow grades on admission andmortality. Two authors independently reviewed abstracts or complete articles.Six studies met inclusion criteria. Independent data extraction was performedby 2 reviewers and confirmed by consensus.Data SynthesisThe 6 trials enrolled 931 STEMI patients treated with abciximab (3 trials)or tirofiban (3 trials) in combination with primary PCI. TIMI grade 2 or 3flow (41.7% [194/465 vs 29.8% [139/466]) as well as TIMI grade 3 flow (20.3%[84/413] vs 12.2% [51/418]) were significantly more frequent in the earlygroup compared with the late group (odds ratio [OR], 1.69; 95% confidenceinterval [CI], 1.28-2.22; P<.001; and OR, 1.85;95% CI, 1.26-2.71; P<.001, respectively). Theearly administration of Gp IIb/IIIa inhibitors was associated with a 28% reductionof mortality from 4.7% to 3.4%, which was not significant but consistent withsimilar trends for reinfarction and the composite ischemic end point.ConclusionsIn a meta-analysis of 6 randomized trials, early administration of GpIIb/IIIa inhibitors in STEMI appeared to improve coronary patency with favorabletrends for clinical outcomes. These findings are supportive of a strategyof facilitated PCI. Further evaluations in adequately powered large trialsare awaited to confirm the clinical benefit of this strategy." @default.
• W2000603887 created "2016-06-24" @default.
• W2000603887 creator A5001104765 @default.
• W2000603887 creator A5006980808 @default.
• W2000603887 creator A5024842277 @default.
• W2000603887 creator A5027244910 @default.
• W2000603887 creator A5056443556 @default.
• W2000603887 date "2004-09-01" @default.
• W2000603887 modified "2023-09-26" @default.
• W2000603887 title "Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. A meta-analysis" @default.
• W2000603887 doi "https://doi.org/10.1016/j.accreview.2004.08.042" @default.
• W2000603887 hasPublicationYear "2004" @default.
• W2000603887 type Work @default.
• W2000603887 sameAs 2000603887 @default.
• W2000603887 citedByCount "0" @default.
• W2000603887 crossrefType "journal-article" @default.
• W2000603887 hasAuthorship W2000603887A5001104765 @default.
• W2000603887 hasAuthorship W2000603887A5006980808 @default.
• W2000603887 hasAuthorship W2000603887A5024842277 @default.
• W2000603887 hasAuthorship W2000603887A5027244910 @default.
• W2000603887 hasAuthorship W2000603887A5056443556 @default.
• W2000603887 hasConcept C126322002 @default.
• W2000603887 hasConcept C164705383 @default.
• W2000603887 hasConcept C2771771 @default.
• W2000603887 hasConcept C2780400711 @default.
• W2000603887 hasConcept C2910310945 @default.
• W2000603887 hasConcept C500558357 @default.
• W2000603887 hasConcept C71924100 @default.
• W2000603887 hasConcept C95190672 @default.
• W2000603887 hasConceptScore W2000603887C126322002 @default.
• W2000603887 hasConceptScore W2000603887C164705383 @default.
• W2000603887 hasConceptScore W2000603887C2771771 @default.
• W2000603887 hasConceptScore W2000603887C2780400711 @default.
• W2000603887 hasConceptScore W2000603887C2910310945 @default.
• W2000603887 hasConceptScore W2000603887C500558357 @default.
• W2000603887 hasConceptScore W2000603887C71924100 @default.
• W2000603887 hasConceptScore W2000603887C95190672 @default.
• W2000603887 hasIssue "9" @default.
• W2000603887 hasLocation W20006038871 @default.
• W2000603887 hasOpenAccess W2000603887 @default.
• W2000603887 hasPrimaryLocation W20006038871 @default.
• W2000603887 hasRelatedWork W2000375143 @default.
• W2000603887 hasRelatedWork W2074910852 @default.
• W2000603887 hasRelatedWork W2104097274 @default.
• W2000603887 hasRelatedWork W2356418186 @default.
• W2000603887 hasRelatedWork W2375576842 @default.
• W2000603887 hasRelatedWork W2384935400 @default.
• W2000603887 hasRelatedWork W2399063111 @default.
• W2000603887 hasRelatedWork W2646582717 @default.
• W2000603887 hasRelatedWork W2918435398 @default.
• W2000603887 hasRelatedWork W3029448752 @default.
• W2000603887 hasVolume "13" @default.
• W2000603887 isParatext "false" @default.
• W2000603887 isRetracted "false" @default.
• W2000603887 magId "2000603887" @default.
• W2000603887 workType "article" @default.